Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CND002
MIFTS: 50

Conduct Disorder

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Conduct Disorder

About this section

MalaCards integrated aliases for Conduct Disorder:

Name: Conduct Disorder 12 73 54 44 15 17 70

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:12995
ICD9CM 34 312.9
MeSH 44 D019955
NCIt 50 C89329
SNOMED-CT 67 430909002
ICD10 32 F91 F91.9
UMLS 70 C0149654
Sources

Summaries for Conduct Disorder

About this section
Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to impulse control disorder and depression. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Aripiprazole and Oxcarbazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and amygdala, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Sources

Related Diseases for Conduct Disorder

About this section

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 31.3 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
2 depression 30.9 TPH1 SLC6A4 MAOA
3 oppositional defiant disorder 30.9 SLC6A4 SLC6A3 OXTR MAOA GABRA2 DRD5
4 alcohol use disorder 30.5 SLC6A4 SLC6A3 GABRA2 DRD2 COMT ALDH2
5 cannabis abuse 30.5 GABRA2 DRD4 DRD2 COMT
6 social phobia 30.5 SLC6A4 MAOA DRD2 COMT
7 antisocial personality disorder 30.5 SLC6A4 SLC6A3 OXTR MAOA GABRA2 DRD4
8 agoraphobia 30.5 SLC6A4 MAOA COMT
9 bipolar i disorder 30.5 SLC6A4 DRD2 COMT
10 tic disorder 30.5 SLC6A4 SLC6A3 MAOA DRD4 DRD2 COMT
11 drug dependence 30.4 SLC6A4 SLC6A3 POMC GABRA2 DRD2
12 brunner syndrome 30.4 TPH1 SLC6A4 MAOA COMT
13 personality disorder 30.3 TPH1 SLC6A4 SLC6A3 OXTR MAOA DRD4
14 obsessive-compulsive personality disorder 30.3 SLC6A4 COMT
15 intermittent explosive disorder 30.3 SLC6A4 MAOA COMT
16 traumatic brain injury 30.2 DRD2 COMT
17 schizoaffective disorder 30.2 SLC6A4 DRD2 COMT
18 asperger syndrome 30.2 SLC6A4 OXTR COMT
19 attention deficit-hyperactivity disorder 30.2 TPH1 SLC6A4 SLC6A3 MAOA DRD5 DRD4
20 borderline personality disorder 30.1 TPH1 SLC6A4 SLC6A3 OXTR MAOA DRD2
21 pervasive developmental disorder 30.1 SLC6A4 OXTR DRD2
22 dysthymic disorder 30.0 SLC6A4 SLC6A3 POMC MAOA DRD4 COMT
23 separation anxiety disorder 30.0 SLC6A4 SLC6A3 OXTR MAOA DRD4 COMT
24 adjustment disorder 30.0 SLC6A4 POMC
25 alexithymia 30.0 SLC6A4 OXTR DRD2 COMT
26 generalized anxiety disorder 29.9 TPH1 SLC6A4 SLC6A3 MAOA DRD2 COMT
27 post-traumatic stress disorder 29.9 SLC6A4 POMC OXTR MAOA DRD2 DBH
28 melancholia 29.9 SLC6A4 POMC MAOA
29 mood disorder 29.8 TPH1 SLC6A4 SLC6A3 POMC MAOA DRD4
30 neurotic disorder 29.8 SLC6A4 POMC MAOA COMT
31 opiate dependence 29.8 TPH1 SLC6A4 SLC6A3 POMC DRD4 DRD2
32 postpartum depression 29.7 SLC6A4 POMC OXTR MAOA COMT
33 bipolar disorder 29.7 TPH1 SLC6A4 SLC6A3 MAOA GABRA2 DRD5
34 psychotic disorder 29.6 TPH1 SLC6A4 SLC6A3 MAOA DRD4 DRD2
35 panic disorder 29.6 TPH1 SLC6A4 SLC6A3 POMC MAOA DRD4
36 mental depression 29.6 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
37 gilles de la tourette syndrome 29.6 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
38 anxiety 29.6 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
39 major depressive disorder 29.5 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
40 substance abuse 29.5 SLC6A4 SLC6A3 POMC MAOA GABRA2 DRD5
41 alcohol dependence 29.4 TPH1 SLC6A4 SLC6A3 POMC MAOA GABRA2
42 tobacco addiction 29.2 TPH1 SLC6A4 SLC6A3 MAOA GABRA2 DRD4
43 body mass index quantitative trait locus 11 29.1 SLC6A3 POMC MAOA DRD4 DRD2 COMT
44 autism spectrum disorder 29.1 SLC6A4 SLC6A3 POMC OXTR MAOA GABRA2
45 substance dependence 29.0 TPH1 SLC6A4 SLC6A3 POMC MAOA GABRA2
46 obsessive-compulsive disorder 29.0 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
47 autism 28.6 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
48 schizophrenia 28.4 TPH1 SLC6A4 SLC6A3 POMC OXTR MAOA
49 migraine with or without aura 1 28.3 TPH1 SLC6A4 SLC6A3 POMC MAOA DRD5
50 disease of mental health 27.5 TPH1 SLC6A4 SLC6A3 POMC OXTR NTSR2

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder
Sources

Symptoms & Phenotypes for Conduct Disorder

About this section

GenomeRNAi Phenotypes related to Conduct Disorder according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.03 MAOA
2 Decreased viability GR00221-A-1 10.03 GABRA2
3 Decreased viability GR00221-A-2 10.03 GABRA2
4 Decreased viability GR00221-A-4 10.03 GABRA2
5 Decreased viability GR00240-S-1 10.03 C5orf15 COMT
6 Decreased viability GR00249-S 10.03 C1QTNF7 COMT NTSR2 SLC6A4 TPH1
7 Decreased viability GR00381-A-1 10.03 C5orf15 NTSR2 SLC6A4
8 Decreased viability GR00381-A-3 10.03 SLC6A4
9 Decreased viability GR00386-A-1 10.03 ALDH2 C1QTNF7 COMT CSRNP3 DBH NTSR2
10 Decreased viability GR00402-S-2 10.03 NTSR2 OXTR
11 Increased the percentage of infected cells GR00402-S-1 8.32 TOX2

MGI Mouse Phenotypes related to Conduct Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 ALDH2 COMT DBH DRD2 DRD4 DRD5
2 cardiovascular system MP:0005385 10.02 ALDH2 COMT DBH DRD2 DRD5 GABRA2
3 homeostasis/metabolism MP:0005376 9.97 ALDH2 C1QTNF7 COMT DBH DRD2 DRD4
4 endocrine/exocrine gland MP:0005379 9.96 ALDH2 COMT DBH DRD2 DRD5 OXTR
5 integument MP:0010771 9.65 ALDH2 DBH DRD2 GABRA2 NTSR2 OXTR
6 nervous system MP:0003631 9.47 ALDH2 COMT DBH DRD2 DRD4 DRD5
Sources

Drugs & Therapeutics for Conduct Disorder

About this section

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Oxcarbazepine Approved Phase 4 28721-07-5 34312
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
5
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
6
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
9 Antidepressive Agents Phase 4
10 Serotonin Receptor Agonists Phase 4
11 Serotonin 5-HT1 Receptor Agonists Phase 4
12 Dopamine agonists Phase 4
13 Sodium Channel Blockers Phase 4
14 Anticonvulsants Phase 4
15 Diuretics, Potassium Sparing Phase 4
16 Sympathomimetics Phase 4
17 Adrenergic Agents Phase 4
18 adderall Phase 4
19 Psychotropic Drugs Phase 4
20 Neurotransmitter Agents Phase 4
21 Dopamine Agents Phase 4
22 Antipsychotic Agents Phase 4
23 Dopamine Antagonists Phase 4
24 Central Nervous System Stimulants Phase 4
25 Dopamine Uptake Inhibitors Phase 4
26
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
27
Lithium carbonate Approved Phase 3 554-13-2
28
Ethanol Approved Phase 2, Phase 3 64-17-5 702
29
Ziprasidone Approved Phase 2 146939-27-7 60854
30
Brexpiprazole Approved, Investigational Phase 1 913611-97-9 11978813
31
tannic acid Approved 1401-55-4
32
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
33
Morphine Approved, Investigational 57-27-2 5288826
34
Testosterone Approved, Investigational 58-22-0 6013
35
Glutamic acid Approved, Nutraceutical 56-86-0 33032
36 Omega 3 Fatty Acid
37 Complement System Proteins
38 Hormones
39 Immunoglobulins
40 Antibodies
41 Antibodies, Antinuclear
42 Anesthetics
43 Androgens
44 Androgen Antagonists
45
Bilirubin 635-65-4 5280352
46 Liver Extracts

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
2 Early Primary Prevention of Conduct Problems Completed NCT00051714 Phase 4
3 A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents Completed NCT00154362 Phase 4 Oxcarbazepine
4 Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
5 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder Recruiting NCT04170738 Phase 4 Adderall
6 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Terminated NCT02063945 Phase 4 Methylphenidate;Risperidone
7 The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Completed NCT00266552 Phase 3 risperidone
8 The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Completed NCT00250354 Phase 3 Risperidone oral solution
9 Long-Term Lithium for Aggressive Conduct Disorder Completed NCT00000385 Phase 3 Lithium;Placebo
10 RCT of an Animal-Assisted Intervention With Adjudicated Youth Completed NCT01594606 Phase 3
11 Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children Completed NCT00399698 Phase 3 Risperdal
12 A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness Completed NCT00344474 Phase 2, Phase 3
13 Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals Completed NCT00776685 Phase 2, Phase 3
14 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
15 Home-based Behavioral Therapy (HBT): Psychosocial Intervention Project for Early Adolescents With Pre- or Early Substance Use Disorder: Phase II Completed NCT00280228 Phase 2
16 Preventive Intervention for Mexican American Adolescents Completed NCT00051727 Phase 2
17 Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial. Completed NCT01494831 Phase 2
18 A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems Completed NCT00626236 Phase 2 SPN-810;SPN-810;SPN-810;SPN-810
19 Intervening Early With Neglected Children: Key Childhood Outcomes Active, not recruiting NCT02093052 Phase 1, Phase 2
20 Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder Withdrawn NCT02247986 Phase 1, Phase 2 Methylphenidate Hydrochloride
21 Treatment of Youth Comorbid Conduct Problems and Depression Unknown status NCT01267773 Phase 1
22 A Clinic-based Program for Families of Depressed Mothers Completed NCT00149812 Phase 1
23 A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
24 Parent Management Training to Prevent Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189
25 A Multiple Biomarker Approach to Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder Unknown status NCT02998073
26 Investigating the Relationship Between Children With ADHD and Conduct Disorder and Their Parents in Reduction of Symptoms Unknown status NCT03691389
27 Prevention and Reduction of Alcohol and Drug Problems in a Clinical Psychiatric Youth Population Unknown status NCT01595568
28 Retrospective Observational Study of Patients With a Sutureless Aortic Valve Implanted in the Cardiovascular and Thoracic Surgery Department of Dijon CHU Unknown status NCT03259945
29 The Good Schools Study: Cluster Randomised Controlled Trial of a Program to Prevent Violence Against Children in Schools Completed NCT01678846
30 A Nutritional and Social Skills Intervention on Conduct Disorder and Hyperactivity Completed NCT00819429
31 PREVENTING CONDUCT DISORDER AMONG CHILDREN IN THE CHILD WELFARE SYSTEM Completed NCT03329625
32 Group-based Parenting Program "Incredible Years" to Reduce Child Conduct Disorder Symptoms in Families With Child Protection and Other Family Support Services in Finland Completed NCT03239990
33 On-line Treatment for Conduct Problems Completed NCT01822392
34 Investigation of Psychophysiological Response to Aversive Stimuli Over Time With Omega-3 Completed NCT03749824
35 Mental Health Services & Predictors of Learning in Urban Schools Completed NCT00612690
36 Investigation of Psychophysiological Correlation of Aggression and Response to Aversive Stimuli Completed NCT03725371
37 Effectiveness of an Anti-bullying Intervention for Adolescent Perpetrators: Using Tools Measuring Brain Function and Structure, Cognition and Behavior. Completed NCT02670876
38 Designing a Novel Behavioral Treatment Protocol for Children Characterized by Conduct Problems and Callous-unemotional Traits Completed NCT01362946
39 Investigating the Neuro-Cognitive Underpinnings of the Emotional Dysfunction Linked to Childhood Behavioral Disturbance Completed NCT00104039
40 Family Groups to Reduce Youth Behavioral Difficulties Completed NCT00404911
41 Can a Physical Activity Program Implemented at a Therapeutic School Promote Emotional Regulation and School Success in Socially and Emotionally Vulnerable Children? Completed NCT02766101
42 The Effectiveness of Parent-Child Interaction Therapy (PCIT) in Treating Behavior Problems in Young Children Completed NCT01085305
43 Effectiveness of Parenting Intervention for Improving Child Mental Health: Randomised Single Blind Controlled Trial Completed NCT03905785
44 Development, Piloting and Evaluation of a Phone-Delivered Psychological Intervention (t-CETA) for Syrian Refugee Children in Lebanon: Phase II Completed NCT03887312
45 Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents (Part of EC FP7 Project Aggressotype: Aggression Subtyping for Improved Insight and Treatment Innovation in Psychiatric Disorders) Completed NCT02485587
46 Randomized Trial of a Transdiagnostic, Cognitive and Behavioral Intervention Versus Treatment as Usual in School-aged Children With Emotional and Behavioral Disturbances Completed NCT03535805
47 Preventing Health Disparities in Hispanic Youth Completed NCT02318745
48 Prevention of Substance Use in At-Risk Students: A Family-Centered Web Program Completed NCT03060291
49 A Family Intervention for Adolescent Problem Behavior Completed NCT01490307
50 Early Family-Centered Prevention of Drug Use Risk Completed NCT01098695

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate

Cochrane evidence based reviews: conduct disorder

Sources

Genetic Tests for Conduct Disorder

About this section
Sources

Anatomical Context for Conduct Disorder

About this section

MalaCards organs/tissues related to Conduct Disorder:

40
Brain, Cortex, Amygdala, Eye, Heart, Liver, Cingulate Cortex
Sources

Publications for Conduct Disorder

About this section

Articles related to Conduct Disorder:

(show top 50) (show all 4016)
# Title Authors PMID Year
1
Variation in the catechol-O-methyltransferase Val 158 Met polymorphism associated with conduct disorder and ADHD symptoms, among adolescent male delinquents. 54 61
19997043 2010
2
Associations of the DRD2 TaqIA polymorphism with impulsivity and substance use: preliminary results from a clinical sample of adolescents. 54 61
19344737 2009
3
Genetic risk for conduct disorder symptom subtypes in an ADHD sample: specificity to aggressive symptoms. 61 54
19465875 2009
4
Monoamine oxidase A and childhood adversity as risk factors for conduct disorder in females. 61 54
18752729 2009
5
Is fetal brain monoamine oxidase inhibition the missing link between maternal smoking and conduct disorders? 61 54
18592036 2008
6
Case-control and within-family tests for an association between conduct disorder and DAT1. 54 61
18197081 2008
7
Testing for gene x environment interaction effects in attention deficit hyperactivity disorder and associated antisocial behavior. 54 61
17579368 2008
8
Adolescent conduct disorder and interpersonal callousness as predictors of psychopathy in young adults. 54 61
17658978 2007
9
A gene x gene interaction between DRD2 and DRD4 is associated with conduct disorder and antisocial behavior in males. 61 54
17587443 2007
10
COMT Val108/158Met gene variant, birth weight, and conduct disorder in children with ADHD. 61 54
17075359 2006
11
MAOA and the "cycle of violence:" childhood abuse and neglect, MAOA genotype, and risk for violent and antisocial behavior. 54 61
16814261 2006
12
Interaction between MAO-A genotype and maltreatment in the risk for conduct disorder: failure to confirm in adolescent patients. 54 61
16741202 2006
13
Gene-environment interaction in hyperkinetic conduct disorder (HD + CD) as indicated by season of birth variations in dopamine receptor (DRD4) gene polymorphism. 54 61
15288435 2004
14
Childhood adversity, monoamine oxidase a genotype, and risk for conduct disorder. 54 61
15237086 2004
15
Associations of the serotonin transporter promoter polymorphism with aggressivity, attention deficit, and conduct disorder in an adoptee population. 61 54
12658617 2003
16
Two dopamine genes related to reports of childhood retrospective inattention and conduct disorder symptoms. 61 54
11443528 2001
17
Dopamine D2 receptor gene (DRD2) is associated with alcoholism with conduct disorder. 54 61
11236830 2001
18
A dinucleotide repeat polymorphism at the gene for monoamine oxidase A and measures of aggressiveness. 61 54
8771218 1995
19
Serum dopamine beta hydroxylase and maltreatment in psychiatrically hospitalized boys. 61 54
7583738 1995
20
Genetic factors in substance abuse based on studies of Tourette syndrome and ADHD probands and relatives. I. Drug abuse. 61 54
8082550 1994
21
Low dopamine-beta-hydroxylase: a biological sequela of abuse and neglect? 54 61
1771204 1991
22
The role of tryptophan metabolic pathway in children with attention deficit hyperactivity disorder with and without comorbid oppositional defiant disorder and conduct disorder. 61
33545424 2021
23
Mental health and psychosocial support in conflict: children's protection concerns and intervention outcomes in Syria. 61
33794955 2021
24
Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark. 61
33743882 2021
25
Association of genetic liability to smoking initiation with e-cigarette use in young adults: A cohort study. 61
33735204 2021
26
Limited Prosocial Emotions in a Clinical Population of Children and Adolescents: Proposal for Core and Ancillary Characteristics: Émotions prosociales limitées dans une population clinique d'enfants et d'adolescents; Proposition de caractéristiques essentielles et accessoires. 61
33787362 2021
27
"You helped me out of that darkness" Children as dialogical partners in the collaborative post-family therapy research interview. 61
33739463 2021
28
Neural processing of socioemotional content in conduct-disordered juvenile offenders with limited prosocial emotions. 61
32735912 2021
29
Emergency Department Admissions for Physical Child Abuse: Evidence from the 2006-2017 Nationwide Emergency Department Sample. 61
33715483 2021
30
Examination of developmental pathways from preschool temperament to early adolescent ADHD symptoms through initial responsiveness to reward. 61
33722319 2021
31
Automated detection of conduct disorder and attention deficit hyperactivity disorder using decomposition and nonlinear techniques with EEG signals. 61
33486340 2021
32
Proximity to traffic and exposure to polycyclic aromatic hydrocarbons in relation to Attention Deficit Hyperactivity Disorder and conduct disorder in U.S. children. 61
33429141 2021
33
Review of Neuropsychological and Electrophysiological Correlates of Callous-unemotional Traits in Children: Implications for EEG Neurofeedback Intervention. 61
33709806 2021
34
Prevalence and Childhood Precursors of Opioid Use in the Early Decades of Life. 61
33369615 2021
35
Assessment of the association between non-suicidal self-injury disorder and suicidal behaviour disorder in females with conduct disorder. 61
33771124 2021
36
The Risk of Making False Confessions: The Role of Developmental Disorders, Conduct Disorder, Psychiatric Symptoms, and Compliance. 61
30895906 2021
37
Poly-victimization and psychopathological symptoms in adolescence: Examining the potential buffering effect of positive childhood experiences. 61
33601709 2021
38
Assessing Callous-Unemotional Traits in 6- to 18-Year-Olds: Reliability, Validity, Factor Structure, and Norms of the German Version of the Inventory of Callous-Unemotional Traits. 61
31096770 2021
39
Prevalence and correlates of police contact amongst youth with bipolar disorder. 61
33561806 2021
40
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol. 61
33472389 2021
41
More is more: Evidence for the incremental value of the SCID-II/SCID-5-PD specific factors over and above a general personality disorder factor. 61
33600207 2021
42
What Predicts Life Satisfaction in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)? A Study from Parent and Child/Adolescent Perspectives. 61
33612131 2021
43
Systematic Review of Electronic Cigarette Use (Vaping) and Mental Health Comorbidity Among Adolescents and Young Adults. 61
32905589 2021
44
Mental Disorders Among Detained Youth: The Hidden Nature and Peculiarities of African Literature. 61
33509405 2021
45
Behavioral symptoms of child mental disorders and lifetime substance use in adolescence: A within-family comparison of US siblings. 61
33385692 2021
46
Cognitive behavior therapy for externalizing disorders in children and adolescents in routine clinical care: A systematic review and meta-analysis. 61
33418192 2021
47
Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH. 61
33583471 2021
48
Psychiatric Morbidity and Behavioral Problems in Children and Adolescents with Bronchial Asthma. 61
33625668 2021
49
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment. 61
32497602 2021
50
Psychiatric comorbidity and social adjustment difficulties in children with disruptive mood dysregulation disorder: A national epidemiological study. 61
33383391 2021
Sources

Variations for Conduct Disorder

About this section
Sources

Expression for Conduct Disorder

About this section
Search GEO for disease gene expression data for Conduct Disorder.
Sources

Pathways for Conduct Disorder

About this section

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Transmission across Chemical Synapses 65
Show member pathways
 12.76 SLC6A4 SLC6A3 MAOA GABRA2 COMT ALDH2
2
Circadian entrainment 36
Show member pathways
 12.52 SLC6A3 MAOA DRD5 DRD4 DRD2 COMT
3
Neuroscience 4
12.44 TPH1 POMC DBH COMT
4
cAMP signaling pathway 36
12.11 POMC OXTR DRD5 DRD2
6
Amphetamine addiction 36
Show member pathways
 11.84 SLC6A3 MAOA DRD2
7
Serotonergic synapse 36
11.82 TPH1 SLC6A4 MAOA
8
Monoamine GPCRs 1
Show member pathways
 11.79 DRD5 DRD4 DRD2
9
Tryptophan metabolism 36 1
Show member pathways
 11.7 TPH1 MAOA ALDH2
10
Amino Acid metabolism 1
11.67 TPH1 MAOA DBH
11
superpathway of tryptophan utilization 1
Show member pathways
 11.63 TPH1 MAOA ALDH2
12
Phenylalanine metabolism 36
Show member pathways
 11.59 MAOA DBH COMT
13
Monoamine Transport 1
Show member pathways
 11.19 SLC6A4 SLC6A3 MAOA DBH
14
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
11.03 TPH1 SLC6A4 MAOA
15
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.9 POMC DRD2
16
Biogenic Amine Synthesis 1
Show member pathways
 10.8 TPH1 MAOA DBH COMT
17
Neurotransmitter Clearance In The Synaptic Cleft 65
Show member pathways
 10.77 SLC6A4 SLC6A3 MAOA COMT ALDH2
18
Dopamine metabolism 1
10.71 MAOA COMT
19
noradrenaline and adrenaline degradation 1
Show member pathways
 10.67 MAOA COMT ALDH2
20
putrescine degradation III 1
Show member pathways
 10.66 MAOA ALDH2
21
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.59 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
22
Propranolol Pathway, Pharmacokinetics 60
10.45 MAOA ALDH2
Sources

GO Terms for Conduct Disorder

About this section

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.13 SLC6A4 SLC6A3 OXTR NTSR2 MYRFL MAOA
2 integral component of presynaptic membrane GO:0099056 9.33 SLC6A4 SLC6A3 DRD2
3 dopaminergic synapse GO:0098691 9.26 SLC6A3 DRD2
4 integral component of plasma membrane GO:0005887 9.23 SLC6A4 SLC6A3 OXTR NTSR2 GABRA2 DRD5
5 integral component of postsynaptic membrane GO:0099055 9.13 SLC6A4 SLC6A3 DRD2

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.94 GABRA2 DRD5 DRD4 DBH
2 response to drug GO:0042493 9.88 SLC6A4 SLC6A3 OXTR DRD2 COMT
3 cellular calcium ion homeostasis GO:0006874 9.83 DRD5 DRD4 DRD2
4 locomotory behavior GO:0007626 9.81 SLC6A3 DRD2 DBH
5 memory GO:0007613 9.79 SLC6A4 OXTR DBH
6 social behavior GO:0035176 9.74 SLC6A4 OXTR DRD4
7 neurotransmitter transport GO:0006836 9.73 SLC6A4 SLC6A3 GABRA2
8 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.67 DRD5 DRD2
9 response to pain GO:0048265 9.67 DBH COMT
10 response to iron ion GO:0010039 9.66 SLC6A3 DRD2
11 behavioral response to cocaine GO:0048148 9.65 DRD4 DRD2
12 neurotransmitter biosynthetic process GO:0042136 9.65 SLC6A4 SLC6A3
13 catecholamine metabolic process GO:0006584 9.65 MAOA COMT
14 prepulse inhibition GO:0060134 9.64 SLC6A3 DRD2
15 maternal behavior GO:0042711 9.63 OXTR DBH
16 neurotransmitter catabolic process GO:0042135 9.62 MAOA COMT
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD4 DRD2
18 regulation of dopamine metabolic process GO:0042053 9.61 SLC6A3 DRD4
19 associative learning GO:0008306 9.61 DRD5 DRD2 DBH
20 monoamine transport GO:0015844 9.6 SLC6A4 SLC6A3
21 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.59 DRD5 DRD2
22 adenohypophysis development GO:0021984 9.58 SLC6A3 DRD2
23 hyaloid vascular plexus regression GO:1990384 9.58 SLC6A3 DRD2
24 dopamine receptor signaling pathway GO:0007212 9.58 DRD5 DRD4 DRD2
25 response to cocaine GO:0042220 9.56 SLC6A3 OXTR DRD5 DRD2
26 sperm ejaculation GO:0042713 9.55 SLC6A4 OXTR
27 fear response GO:0042596 9.54 DRD4 DBH
28 dopamine metabolic process GO:0042417 9.54 DRD4 DRD2 COMT
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.52 DRD4 DRD2
30 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.51 OXTR DRD5
31 synaptic transmission, dopaminergic GO:0001963 9.5 DRD5 DRD4 DRD2
32 response to histamine GO:0034776 9.49 DRD4 DRD2
33 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.46 DRD4 DRD2
34 behavioral response to ethanol GO:0048149 9.33 DRD4 DRD2 DBH
35 dopamine catabolic process GO:0042420 9.26 SLC6A3 MAOA DBH COMT
36 response to amphetamine GO:0001975 9.02 OXTR DRD5 DRD4 DRD2 DBH

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter transporter activity GO:0005326 9.32 SLC6A4 SLC6A3
2 monoamine transmembrane transporter activity GO:0008504 9.26 SLC6A4 SLC6A3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD4 DRD2
4 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD5 DRD4 DRD2
5 dopamine binding GO:0035240 8.92 SLC6A3 DRD5 DRD4 DRD2
Sources

Sources for Conduct Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....